---
document_datetime: 2025-12-11 14:10:59
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/hyrimoz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: hyrimoz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.3775425
conversion_datetime: 2025-12-23 03:26:08.380385
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Hyrimoz

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a variation | 11/12/2025                          | N/A                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000295410                        | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z - to update the Risk Management Plan (RMP) for Hyrimoz and Hefiya (duplicate of Hyrimoz) to align it with the originator's (Humira) RMP.   |            |            |                        |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| Variation type IA_IN / EMA/VR/0000308055 | B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted                                                                                                                                                                                                                                                                                                           | 13/11/2025 |            | SmPC, Labelling and PL |
| Variation type IA / EMA/VR/0000286033    | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.d Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) - Accepted                                                                                                                                                                    | 30/07/2025 | N/A        |                        |
| Variation type IB / EMA/VR/0000245174    | This was an application for a variation following a worksharing procedure according                                                                                                                                                                                                                                                                                                                                                                                                | 25/04/2025 | 21/11/2025 | Annex II               |

<div style=\"page-break-after: always\"></div>

|                     | to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.e.5 Implementation of changes foreseen in an approved change management protocol - B.I.e.5.c Implementation of a change for a biological/immunological medicinal product - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |     |                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IB / | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a | 10/04/2025 | N/A | EMA/VR/0000253695 |

<div style=\"page-break-after: always\"></div>

|                                       | batch control/testing takes place - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                                                                                                                                                                                                                     |            |     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000241703 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted | 20/02/2025 | N/A |